Articles tagged with Molecular Imaging
Researchers developed a DOTA-conjugated NTR1 antagonist to treat and monitor pancreatic cancer, showing significant tumor growth inhibition in early studies. The novel procedure was well-tolerated by patients, with one experiencing improved symptoms and quality of life.
A new PET tracer has shown potential in predicting treatment effectiveness for depression by measuring the level of serotonin transporter protein in the brain. The study found that patients who responded to treatment had lower levels of this protein before treatment began, suggesting a biomarker for remission.
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
Researchers developed a new approach that uses a single PET scan to assess PD-L1 positive tumors, enabling personalized cancer treatment. The study demonstrates the feasibility of this non-invasive method, which may help guide treatment decisions and assess treatment response.
The new TILT3D microscope produces clear 3-D images of structures and individual molecules within a cell, overcoming existing illumination techniques' limitations. Researchers can track the 3-D movement of molecules over time with high precision, enabling detailed studies of cellular structures.
The Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology have issued joint guidelines for the clinical quantification of myocardial blood flow using Positron Emission Tomography (PET). The guidelines provide a comprehensive framework for the measurement and interpretation of myocardial blood ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
The new total-body PET/CT scanner will advance clinical research and patient care by providing better imaging data from the whole body, reducing radiation exposure and increasing sensitivity. This technology has the potential to change cancer detection and staging methods, as well as improve diagnosis for other systemic conditions.
A new PET tracer has been developed to effectively gauge the effectiveness of promising Alzheimer's treatments in mouse models. The tracer binds to BACE1, a key enzyme involved in amyloid-β development, and accurately measures its effects on brain metabolism, neuroinflammation, and amyloid-β pathology.
A new sensor molecule allows researchers to visualize calcium concentrations in living animals without genetic modification or radiation exposure. This breakthrough enables better understanding of disease processes and has potential applications in improving medical treatments.
INRS professors François Légaré and Federico Rosei have been elected OSA Fellows for their groundbreaking work in ultrafast molecular imaging and photonic materials development. The distinction reflects their leadership, publication record, and significant impact on optics and photonics research.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT imaging in cancer patients. The AUC aims to improve the utilization of this technology and provide guidance for providers across specialties.
Researchers report on a new dosing regimen for actinium-225 labeled targeted alpha therapy, showing promising anti-tumor response in patients with PSMA-positive tumors. The treatment protocol balances treatment response with toxicity concerns to provide effective therapy with minimal side effects.
Theranostics combines predictive biomarkers and precise therapy to target cancer cells, minimizing side effects. The field is expected to change nuclear medicine from 'nuclear radiology' to true 'nuclear medicine,' with potential for cures.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of the 2017-2019 Wagner-Torizuka Fellowship. The two-year fellowship provides extensive training and experience in nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. This year's fellows are Sho Mo...
A new approach to optical imaging allows for fast and economical tracking of multiple molecular interactions in large areas of living tissue. The method, developed by Rensselaer Polytechnic Institute researchers, can capture interactions in mere billionths of a second and simultaneously track 16 colors of spatially linked information.
Researchers at Case Western Reserve University have developed a new multicolor MRI method that enables simultaneous detection of two different contrast agents, allowing for immediate comparisons of diseased and healthy tissue. This breakthrough has the potential to transform molecular imaging and aid disease diagnosis.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. The new guidelines aim to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services, helping referring physicians make informed decisions.
The Society of Nuclear Medicine and Molecular Imaging recognized Robert E. Henkin, MD, for his 30-year dedication to the field of nuclear medicine, while John M. Hoffman, MD, was honored for his expertise in molecular imaging research and leadership roles in the SNMMI Clinical Trials Network.
Researchers developed a novel imaging tracer that allows for early assessment of abdominal aortic aneurysm (AAA) risk. The study shows high sensitivity and specificity in detecting vessel wall biology, suggesting a promising tool for AAA risk stratification.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized the work of several award-winning nuclear medicine technologists, including Amanda Abbott, Dusty M. York, Cindi Luckett-Gilbert, Margaret M. Doonan, and Robert A. Pagnanelli, for their contributions to education and service in the field.
Monash University researchers have identified a key part of the process by which a common clinical antibiotic is formed, paving the way for novel compounds to tackle bacterial resistance. By understanding this process, scientists can manipulate it to create modified compounds that could help combat superbugs.
A Phase II study found that increasing radiotherapy doses to hypoxic non-small cell lung cancer (NSCLC) lesions, identified by PET/CT scans, did not improve patient outcomes. The study suggests that smaller volumes of tumors with hypoxia may be more effectively targeted for radiotherapy.
Researchers have developed a novel PET tracer that can detect small blood clots in veins and arteries, providing valuable information for diagnosis and treatment. The tracer binds to GPIIb/IIIa receptors, targeting the critical molecular components involved in platelet clumping.
The Journal of Nuclear Medicine ranked 5th in impact factor among medical imaging journals, increasing to 6.646 in 2016, with a 5-year impact factor of 6.459. Citations increased to 24,977, and article influence score is 1.84.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.
Researchers found that dual-agent PET/MR with time of flight detects more bone metastases in breast and prostate cancer patients, improving detection accuracy and reducing radiation dose. The study used combined imaging agents <sup>18</sup> F-FDG and <sup>18</sup> F-NaF to enhance image quality.
A new study demonstrates the feasibility and safety of HuMab-5B1, an antibody that targets the cancer antigen 19-9, found on pancreatic tumors and other malignancies. The treatment shows promise for better identifying tumors and directing treatment.
A single dual time-point PET scan can identify two important biomarkers of Alzheimer's disease: neuronal injury and amyloid load. This non-invasive method shows promise for early diagnosis and personalized treatment.
Researchers found that combining peptide-receptor radionuclide therapy (PRRT) with a PARP inhibitor significantly slows the growth of neuroendocrine tumors. The treatment combination induced more cell death and inhibited cell proliferation in both gastroenteropancreatic and bronchopulmonary NET cell lines.
The Society of Nuclear Medicine and Molecular Imaging recognized seven new SNMMI Fellows for their distinguished service and exceptional achievements in the field. The fellows include past SNMMI presidents, renowned experts, and leaders in nuclear medicine and molecular imaging.
Researchers developed a personalized peptide-receptor radionuclide therapy (PRRT) approach, which increased the radiation dose to tumors by up to three times. The treatment showed reduced side effects and improved safety profiles without compromising therapeutic benefits.
Fowler has made significant contributions to brain research, developing the radiotracer F-18-FDG to measure brain glucose metabolism non-invasively in humans. Her work has facilitated advances in the study of the human brain and malignant tumor detection.
A study found that brain receptors involved in addiction adapt to chronic drinking by reducing their bioavailability, but return to normal after detoxification. This can serve as a predictor of long-term sobriety success.
Pomper is recognized for his work on developing new imaging agents targeting cancer and central nervous system processes. He oversees several federally funded programs at Johns Hopkins, advancing the field of molecular imaging.
Researchers developed a scanner that unites optical, radioluminescence, and photoacoustic imaging to evaluate thin-cap fibro atheroma (TCFA) in the earliest stages. This could lead to a paradigm shift in coronary artery disease diagnosis and assessment.
The grants will support pre-clinical and clinical diagnostic and therapeutic research, including the development of new imaging agents and clinical trials on therapy safety and efficacy. The Brain SAFTIE initiative aims to identify gaps in existing knowledge and facilitate collaboration among experts.
Researchers demonstrated the efficacy of targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery, using a PSMA-targeting agent coupled with photosensitizers. The technique optimizes prostate cancer care by allowing visualization of tumors prior to surgery and providing real-time guidance to surgeons.
Experts argue against the linear no-threshold hypothesis, citing evidence of adaptive responses that repair mutations or remove damaged cells. The authors suggest that diagnostic quality and accurate information are more important than erring on the side of caution in reducing radiation exposure.
Researchers develop new protocol using PaCO2 to amplify myocardial blood flow, offering an alternative to injectable pharmacological agents. The study shows a safe and effective method for widening heart blood vessels during stress tests, benefiting patients with severe side effects from traditional methods.
Researchers have developed a new technique using Cerenkov luminescence imaging (CLI) to assess tumor margins during breast tumor surgery. This method combines optical and molecular imaging, providing high-resolution images of the tumor and surrounding tissue.
Researchers developed a dual-modality imaging technique using SPECT/CT and fluorescence to detect micrometastases in colorectal cancer. This approach can guide resection of tumor lesions and potentially improve prognosis for cancer patients.
Researchers used PET/CT scans to determine the potential effectiveness of bevacizumab treatment in children with diffuse intrinsic pontine glioma (DIPG). The study found that non-invasive imaging can help predict therapeutic potential and toxicity, paving the way for personalized medicine approaches.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria for ventilation/perfusion imaging in pulmonary embolism. The guidelines aim to promote cost-effective and appropriate utilization of advanced diagnostic imaging services, affecting approximately 300,000 Americans each year.
Cytomegalovirus has evolved to hide from the immune system by presenting decoy markers, tricking NK cells into thinking infected cells are healthy. The immune system responds by evolving new mechanisms to detect and kill the virus, including a molecule called NK1.1.
Researchers developed new engineered PET tracers to image immune checkpoint expression in cancer cells, enabling monitoring of targeted immunotherapy. The study shows practical immunoPET radiotracer design modifications and their effects on human PD-L1 immune checkpoint imaging.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for bone scintigraphy in patients with prostate or breast cancer. The new AUC aim to improve healthcare outcomes by making the use of bone scintigraphy more consistent and reducing unnecessary imaging costs.
Researchers found that Fluciclovine PET/CT significantly improved targeted therapy for recurrent prostate cancer by defining tumor-targeted areas. The treatment led to higher radiation doses to the penile bulb without increased toxicity.
Researchers develop a new PET radiotracer that can quickly identify life-threatening atherosclerotic plaques by detecting inflammation. This breakthrough has the potential to prevent heart attacks and strokes by allowing for early treatment of atherosclerosis.
Researchers at Max Planck Institute for Chemical Ecology have developed a new technique to visualize molecular distributions on rippled, hairy, or bulgy surfaces. The 'corrective glass' method uses laser ablation electrospray ionization (LAESI) to correct for surface topography and provide accurate chemical imaging.
A new gallium-68 labeled peptide BBN-RGD agent has been developed to target both gastrin-releasing peptide receptor and integrin αvβ3, providing dual-receptor targeting and advantages over single-receptor targeting. The agent has shown safety and effectiveness in detecting primary and metastatic prostate cancer lesions.
Researchers have developed an image analysis technique called Hyper-Spectral Phasor (HySP) that can track multiple molecules in living organisms, making it easier to diagnose diseases and identify therapeutic targets. The new technology uses cell phone images and is faster and less expensive than current methods.
Researchers argue that the linear no-threshold hypothesis, which suggests all radiation is harmful, is inaccurate and has led to widespread fear of low-dose radiation. Studies show that low doses stimulate protective responses, reducing cancer risk rather than increasing it.
A German multicenter study confirms the efficacy and safety of Lu-177-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer, demonstrating a positive response rate of 45% and manageable side effects. The treatment offers an additional option for end-stage patients with high response rates and low toxicity.
Molecular imaging techniques have the potential to revolutionize cancer diagnosis, monitoring, and treatment by providing non-invasive alternatives to traditional biopsies. By identifying specific biomarkers, these methods can help doctors choose the most effective treatments, minimize side effects, and predict patient outcomes.
Researchers developed low-cost 3D printed organ models of varying size and shape to aid in determining optimal dosing for individual patients. The study demonstrates the potential of 3D printing technology for clinical prototyping, particularly in quantitative SPECT/CT imaging.